ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated

Oric Pharmaceuticals, Inc.

2024-FY EPS reported -$1.83

Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.
R&D expenses Q4 $32.0M (up 31% YoY), FY2024 $114.1M (up 34%).
G&A expenses Q4 $7.6M (up 10%), FY2024 $28.8M (up 13%).
Expects seven data readouts for ORIC-114, ORIC-944 over 18 months; potential registrational trials in 2H25/early 2026.
Entered J&J collaboration for ORIC-114 + amivantamab in NSCLC; completed $125M private placement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.